Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Ongoing, no longer enrolling
Registry enrollment: 341 participants
Study ages: 18 Years and older
No results-posting date in this record
Read trial record and resultsChecked Nov 17, 2026